PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-3.93%
Negative revenue growth while Drug Manufacturers - Specialty & Generic median is -1.63%. Seth Klarman would investigate if the company is losing market share or facing a declining industry.
-34.20%
Negative gross profit growth while Drug Manufacturers - Specialty & Generic median is 1.45%. Seth Klarman would suspect poor product pricing or inefficient production.
61.81%
EBIT growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 13.54%. Joel Greenblatt would examine whether a unique competitive edge supports this outperformance.
61.81%
Operating income growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 12.98%. Joel Greenblatt would see if unique processes drive exceptional profitability.
53.38%
Net income growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 18.43%. Joel Greenblatt would check if brand strength or cost advantages fuel this outperformance.
55.11%
EPS growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 25.00%. Joel Greenblatt would confirm if consistent earnings expansion underpins these gains.
55.11%
Diluted EPS growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 25.00%. Joel Greenblatt would confirm if strong net income growth or buybacks drive outperformance.
5.26%
Share growth above Drug Manufacturers - Specialty & Generic median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
5.26%
Diluted share growth above 2x Drug Manufacturers - Specialty & Generic median. Jim Chanos would suspect undue issuance or heavy employee stock compensation.
No Data
No Data available this quarter, please select a different quarter.
-136.34%
Negative OCF growth while Drug Manufacturers - Specialty & Generic median is -16.66%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-164.10%
Negative FCF growth while Drug Manufacturers - Specialty & Generic median is -6.96%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
373.08%
5Y revenue/share growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 16.53%. Joel Greenblatt would see if the company’s moat drives rapid mid-term expansion.
-43.99%
Negative 3Y CAGR while Drug Manufacturers - Specialty & Generic median is 8.33%. Seth Klarman would examine if the sector is otherwise stable, indicating a company-specific issue.
-41900.71%
Negative 10Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
60.67%
OCF/share CAGR of 60.67% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
89.54%
3Y OCF/share growth > 1.5x Drug Manufacturers - Specialty & Generic median of 3.88%. Joel Greenblatt might see a recent competitive advantage translating into cash improvements.
-3781.62%
Negative 10Y net income/share CAGR vs. Drug Manufacturers - Specialty & Generic median of 48.60%. Seth Klarman might see a fundamental problem if peers maintain growth.
-193.75%
Negative 5Y CAGR while Drug Manufacturers - Specialty & Generic median is 32.39%. Seth Klarman might see a specific weakness if peers maintain profitable expansions.
-402.19%
Negative 3Y CAGR while Drug Manufacturers - Specialty & Generic median is 16.79%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
5906.98%
Equity/share CAGR exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 39.23% over 10 years. Joel Greenblatt would see if a high ROE underlies this compounding advantage.
-16.70%
Negative 5Y equity/share growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman suspects firm-specific weaknesses if peers grow equity mid-term.
-14.43%
Negative 3Y equity/share growth while Drug Manufacturers - Specialty & Generic median is -8.97%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.81%
AR shrinking while Drug Manufacturers - Specialty & Generic median grows. Seth Klarman sees potential advantage unless it signals declining demand.
15.72%
Inventory growth far above Drug Manufacturers - Specialty & Generic median. Jim Chanos suspects major issues in demand forecasting or potential obsolescence risk.
2.21%
We expand assets while Drug Manufacturers - Specialty & Generic is negative. Peter Lynch sees a possible advantage if expansions align with profitable markets or a recovering cycle.
-2.95%
Negative BV/share change while Drug Manufacturers - Specialty & Generic median is -0.72%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
-4.65%
Debt is shrinking while Drug Manufacturers - Specialty & Generic median is rising. Seth Klarman might see an advantage if growth remains possible.
-56.11%
R&D dropping while Drug Manufacturers - Specialty & Generic median is rising. Seth Klarman wonders if we risk ceding future innovation or if peers overspend.
-13.48%
SG&A decline while Drug Manufacturers - Specialty & Generic grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.